Clinical Trial

9-ING-41 in Patients With Advanced Cancers

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Protocol Amendment History 49 amendments
This ClinicalTrials.gov record has been amended 49 times since 2018-09-18; most recent amendment 2026-03-30.
Status change: Recruiting → Active, Not Recruiting 2024-01-29
Status change: Not Yet Recruiting → Recruiting 2018-12-07
Trial Details
NCT Number NCT03678883
Lead Sponsor Actuate Therapeutics Inc.
Conditions Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma +17 more
Enrollment 350 participants
Start Date 2019-01-04
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-03